SurModics Inc (SRDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SurModics Inc (SRDX) has a cash flow conversion efficiency ratio of 0.013x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.41 Million) by net assets ($111.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of SurModics Inc to measure how many days the company can operate on defensive assets alone.
SurModics Inc - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how SurModics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
SurModics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SurModics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fuan Pharmaceutical Group Co
SHE:300194
|
0.023x |
|
Nanjing Medlander Medical Technology Co. Ltd. A
SHG:688273
|
N/A |
|
Surya Roshni Limited
NSE:SURYAROSNI
|
0.098x |
|
Alpha Tau Medical Ltd
NASDAQ:DRTS
|
0.000x |
|
Suzhou Alton Electrical & Mechanical Industry Co. Ltd.
SHE:301187
|
-0.070x |
|
MarineMax Inc
NYSE:HZO
|
0.018x |
|
NorthIsle Copper and Gold Inc
V:NCX
|
-0.071x |
|
Castle Biosciences Inc
NASDAQ:CSTL
|
-0.048x |
Annual Cash Flow Conversion Efficiency for SurModics Inc (1998–2024)
The table below shows the annual cash flow conversion efficiency of SurModics Inc from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see SurModics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $118.90 Million | $248.00K | 0.002x | -97.62% |
| 2023-09-30 | $119.91 Million | $10.51 Million | 0.088x | +155.18% |
| 2022-09-30 | $108.39 Million | $-17.22 Million | -0.159x | -244.64% |
| 2021-09-30 | $140.09 Million | $15.39 Million | 0.110x | +2.76% |
| 2020-09-30 | $131.06 Million | $14.01 Million | 0.107x | +62.94% |
| 2019-09-30 | $122.52 Million | $8.04 Million | 0.066x | -79.07% |
| 2018-09-30 | $108.61 Million | $34.05 Million | 0.314x | +148.89% |
| 2017-09-30 | $111.56 Million | $14.05 Million | 0.126x | -46.52% |
| 2016-09-30 | $106.83 Million | $25.17 Million | 0.236x | +46.43% |
| 2015-09-30 | $93.37 Million | $15.02 Million | 0.161x | -12.64% |
| 2014-09-30 | $98.75 Million | $18.18 Million | 0.184x | -2.20% |
| 2013-09-30 | $93.82 Million | $17.66 Million | 0.188x | +10.66% |
| 2012-09-30 | $94.69 Million | $16.11 Million | 0.170x | +23.92% |
| 2011-09-30 | $145.34 Million | $19.95 Million | 0.137x | -3.70% |
| 2010-09-30 | $154.36 Million | $22.01 Million | 0.143x | -21.53% |
| 2009-09-30 | $172.37 Million | $31.32 Million | 0.182x | -35.29% |
| 2008-09-30 | $141.81 Million | $39.82 Million | 0.281x | -27.50% |
| 2007-09-30 | $130.92 Million | $50.71 Million | 0.387x | +59.43% |
| 2006-09-30 | $145.20 Million | $35.28 Million | 0.243x | +8.22% |
| 2005-09-30 | $115.58 Million | $25.95 Million | 0.225x | +8.85% |
| 2004-09-30 | $94.50 Million | $19.49 Million | 0.206x | -7.77% |
| 2003-09-30 | $86.11 Million | $19.26 Million | 0.224x | +9.36% |
| 2002-09-30 | $70.00 Million | $14.31 Million | 0.204x | +45.82% |
| 2001-09-30 | $55.70 Million | $7.81 Million | 0.140x | -8.18% |
| 2000-09-30 | $48.30 Million | $7.38 Million | 0.153x | +3.09% |
| 1999-09-30 | $29.70 Million | $4.40 Million | 0.148x | +60.14% |
| 1998-09-30 | $22.70 Million | $2.10 Million | 0.093x | -- |
About SurModics Inc
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision o… Read more